Vivos Therapeutics Inc. entered into a convertible promissory note with V-Co Investors 2 LLC, an affiliate of New Seneca Partners Inc., on May 21, 2025, for a principal amount of $1,100,000. The transaction was part of a private placement, exempt from registration under Section 4(a)(2) of the Securities Act. There is no specific mention of share transactions, total number of shares, or price in the document provided.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.